The math doesn’t add up.
We have to toe the party line, but the basic numbers don’t add up. Spend vs Return. Fanapt goes off patent in less than 2 years. In a best case they get the follow on molecule approved. Every patient will still have to step through generic. The fundamentals say they won’t make back the spend even when you don’t include clinical costs.
